Alliance Pharma completes acquisition of Vamousse from Tyratech

AIM-listed specialty pharmaceutical group Alliance Pharma has completed the acquisition of the worldwide rights to the Vamousse lice treatment range from Tyratech.

The deal was done through Alliance’s wholly-owned subsidiary, Alliance Pharmaceuticals.

The company also said on Thursday that it has appointed Amanda Sicvol as Country Manager for its newly-created US affiliate. It said Sicvol has been instrumental in the commercial success of Vamousse to date, having worked for Tyratech for four years.

Alliance chief executive officer John Dawson said: “The completion of this acquisition provides Alliance a third International star brand with best in class technology. There is also real potential for further growth through our substantial global network of distributors. We are delighted to welcome Amanda to Alliance to establish our presence in the US, the largest consumer healthcare market in the world."

Earlier this month, Alliance said it had agreed to pay an initial consideration of $13m and deferred contingent consideration of up to $4.5m.

At 1110 GMT, the shares were up 1.5% to 63.97p.